Combination therapy improves overall survival in women with advanced breast cancer

[News]

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

More... (http://www.news-medical.net/news/20091214/Combination-therapy-improves-overall-survival-in-women-with-advanced-breast-cancer.aspx)